AtriCure Inc. (ATRC) Expected to Announce Quarterly Sales of $50.94 Million

Equities research analysts expect AtriCure Inc. (NASDAQ:ATRC) to announce sales of $50.94 million for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for AtriCure’s earnings. The highest sales estimate is $51.20 million and the lowest is $50.70 million. AtriCure posted sales of $46.06 million in the same quarter last year, which suggests a positive year-over-year growth rate of 10.6%. The firm is scheduled to announce its next earnings results on Monday, February 25th.

According to Zacks, analysts expect that AtriCure will report full year sales of $199.63 million for the current fiscal year, with estimates ranging from $199.50 million to $199.90 million. For the next financial year, analysts forecast that the firm will post sales of $222.02 million, with estimates ranging from $220.20 million to $225.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for AtriCure.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Thursday, November 1st. The medical device company reported ($0.24) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.02). AtriCure had a negative net margin of 10.41% and a negative return on equity of 16.92%. The business had revenue of $49.90 million during the quarter, compared to analysts’ expectations of $49.90 million. During the same quarter in the previous year, the firm earned ($0.22) earnings per share. AtriCure’s revenue was up 18.2% on a year-over-year basis.

A number of research firms recently commented on ATRC. Zacks Investment Research downgraded AtriCure from a “hold” rating to a “sell” rating in a research report on Monday, August 6th. Needham & Company LLC boosted their target price on AtriCure from $36.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, October 4th. Canaccord Genuity boosted their target price on AtriCure from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, October 9th. Finally, BidaskClub downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 13th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $36.20.

Large investors have recently bought and sold shares of the stock. AMS Capital Ltda bought a new stake in AtriCure during the third quarter worth approximately $725,000. Sei Investments Co. increased its stake in AtriCure by 958.4% during the second quarter. Sei Investments Co. now owns 42,960 shares of the medical device company’s stock worth $1,162,000 after acquiring an additional 38,901 shares during the last quarter. Quantum Capital Management increased its stake in AtriCure by 5.0% during the second quarter. Quantum Capital Management now owns 114,345 shares of the medical device company’s stock worth $3,093,000 after acquiring an additional 5,458 shares during the last quarter. TD Asset Management Inc. increased its stake in AtriCure by 87.7% during the second quarter. TD Asset Management Inc. now owns 64,600 shares of the medical device company’s stock worth $1,747,000 after acquiring an additional 30,184 shares during the last quarter. Finally, FMR LLC increased its stake in AtriCure by 1.4% during the second quarter. FMR LLC now owns 5,255,607 shares of the medical device company’s stock worth $142,164,000 after acquiring an additional 71,961 shares during the last quarter. Institutional investors own 81.70% of the company’s stock.

Shares of AtriCure stock traded down $0.73 during trading hours on Tuesday, hitting $32.29. The company’s stock had a trading volume of 205,800 shares, compared to its average volume of 211,003. AtriCure has a 12-month low of $14.88 and a 12-month high of $36.49. The company has a market capitalization of $1.29 billion, a price-to-earnings ratio of -38.90 and a beta of 0.12. The company has a quick ratio of 1.96, a current ratio of 2.62 and a debt-to-equity ratio of 0.31.

AtriCure Company Profile

AtriCure, Inc provides atrial fibrillation solutions to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy; and EPi-Sense guided coagulation system used for the temporary cardiac signal sensing and recording during surgery.

Recommended Story: Outstanding Shares and The Effect on Share Price

Get a free copy of the Zacks research report on AtriCure (ATRC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AtriCure (NASDAQ:ATRC)

Receive News & Ratings for AtriCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit